Abstract
Renal and cardiac function are greatly affected by chronic oxidative stress which can cause many pathophysiological states. The Na/K-ATPase is well-described as an ion pumping enzyme involved in maintaining cellular ion homeostasis; however, in the past two decades, extensive research has been done to understand the signaling function of the Na/K-ATPase and determine its role in physiological and pathophysiological states. Our lab has shown that the Na/K-ATPase signaling cascade can function as an amplifier of reactive oxygen species (ROS) which can be initiated by cardiotonic steroids or increases in ROS. Regulation of systemic oxidative stress by targeting Na/K-ATPase signaling mediated oxidant amplification improves 5/6th partial nephrectomy (PNx) mediated uremic cardiomyopathy, renal sodium handling, as well as ameliorates adipogenesis. This review will present this new concept of Na/K-ATPase signaling mediated oxidant amplification loop and its clinic implication.
Keywords: Na/K-ATPase, signaling, ROS, oxidative stress, ion homeostasis, pumping enzyme.
Current Pharmaceutical Design
Title:Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Volume: 24 Issue: 3
Author(s): Jiang Liu, Megan N. Lilly and Joseph I. Shapiro*
Affiliation:
- Department of Medicine, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV,United States
Keywords: Na/K-ATPase, signaling, ROS, oxidative stress, ion homeostasis, pumping enzyme.
Abstract: Renal and cardiac function are greatly affected by chronic oxidative stress which can cause many pathophysiological states. The Na/K-ATPase is well-described as an ion pumping enzyme involved in maintaining cellular ion homeostasis; however, in the past two decades, extensive research has been done to understand the signaling function of the Na/K-ATPase and determine its role in physiological and pathophysiological states. Our lab has shown that the Na/K-ATPase signaling cascade can function as an amplifier of reactive oxygen species (ROS) which can be initiated by cardiotonic steroids or increases in ROS. Regulation of systemic oxidative stress by targeting Na/K-ATPase signaling mediated oxidant amplification improves 5/6th partial nephrectomy (PNx) mediated uremic cardiomyopathy, renal sodium handling, as well as ameliorates adipogenesis. This review will present this new concept of Na/K-ATPase signaling mediated oxidant amplification loop and its clinic implication.
Export Options
About this article
Cite this article as:
Liu Jiang , Lilly N. Megan and Shapiro I. Joseph*, Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress, Current Pharmaceutical Design 2018; 24 (3) . https://dx.doi.org/10.2174/1381612824666180110101052
DOI https://dx.doi.org/10.2174/1381612824666180110101052 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design The Tangled Mitochondrial Metabolism in Cancer: An Innovative Pharmacological Approach
Current Medicinal Chemistry Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets